{"id":995181,"date":"2026-08-13T16:37:55","date_gmt":"2026-08-13T20:37:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-reports-20-year-over-year-revenue-growth-for-the-third-fiscal-quarter-of-2026\/"},"modified":"2026-08-13T16:37:55","modified_gmt":"2026-08-13T20:37:55","slug":"cbdmd-reports-20-year-over-year-revenue-growth-for-the-third-fiscal-quarter-of-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-reports-20-year-over-year-revenue-growth-for-the-third-fiscal-quarter-of-2026\/","title":{"rendered":"cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Accelerating Oasis Beverage Momentum, a Full Quarter of Bluebird Botanical Contribution, and Advancing Federal Hemp Legislation Strengthen the Company’s Positioning for Competing under Pending Federal Regulations<\/i>
\n <\/b>\n <\/p>\n

\n CHARLOTTE, N.C.<\/span>, Aug. 13, 2026<\/span> \/PRNewswire\/ — cbdMD, Inc. (NYSE American: YCBD), one of the nation’s leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its hemp-derived THC beverage brand Oasis and functional-mushroom brand ATRx Labs, today announced financial results for the third quarter of fiscal year 2026, ended June 30, 2026.<\/p>\n

\n

\n \"cbdMD\n <\/p>\n<\/p><\/div>\n

The Company delivered 20% year-over-year revenue growth, driven by a 61% increase in wholesale net sales, increased distribution of its Oasis beverage brand, and the first full quarter of contribution from the recently acquired Bluebird Botanicals.<\/p>\n

“The third quarter was another quarter of top-line growth and real strategic progress,” said Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD. “Revenue was up 20% year-over-year, our Oasis beverage brand sales continued to grow, and Bluebird Botanicals contributed a full quarter of revenue for the first time. We were not satisfied with our bottom line this quarter but the shortfall was largely the result of deliberate choices. We absorbed one-time costs tied to M&A due diligence and other one-time legal costs, continued to invest in product development, and did the work required to resolve supply-chain and address state-level compliance issues. During July we implemented cost reduction initiatives that we expect to result in saving potential up to $150,000 per month, as we are running the business to be leaner, more flexible, and well positioned to succeed in the market following the effectiveness of pending federal regulation.”<\/p>\n

“The regulatory picture is also moving in a more constructive direction,” Kennedy continued. “A Senate-driven extension has given cbdMD and the broader industry additional time ahead of the November effective date of the H.R. 5371 Sec. 781<\/b><\/a>\u00a0legislation to ensure company compliance with the pending laws, and the number of bipartisan legislative proposals continues to grow, including the Beverage Regulatory Parity Act introduced this week, which would regulate hemp-derived beverages much like alcohol. We believe momentum is building toward a workable federal framework, and that well-capitalized, compliance-focused operators with proven quality, safety data, and clinical credibility, such as cbdMD, will be the ones that benefit as clarity emerges.”<\/p>\n

\n Highlights for the Third Quarter of Fiscal 2026 and Notable Business Updates<\/b>\n <\/p>\n